Keywords

AML palliative care, Disease burden, End-of-life care, Hematology

 

Authors

  1. Hopkins, Bianca BSN
  2. Gold, Michelle MBBS(Hons), FRACP
  3. Wei, Andrew PhD, MBBS(Hons), FRACP, FRCPA
  4. Grigoriadis, George PhD, MBBS (Hons), FRACP, FRCPA

Abstract

Background: Currently, there is little guidance available for documenting and executing the change in management goals in the context of incurable hematologic disease.

 

Objective: The aim of this study was to improve the transition to palliative care for patients with acute myeloid leukemia (AML) through the development and implementation of a coordinated care plan program.

 

Methods: Twenty-three patients with AML who were no longer being treated with curative intent from March 2011 through September 2012 had hematology supportive care plans developed. Patients (n = 7) completed post-care plan implementation questionnaires to determine their level of understanding in relation to the change in treatment intent. Staff completed pre- (n = 26) and post- (n = 19) care plan implementation questionnaires to determine the communication, challenges, and accessibility of changed management goals.

 

Results: Seventy-seven percent of patients understood palliative care to be the primary team managing their symptoms, with 75% of patients viewing symptom control as the main goal of treatment. Staff findings demonstrated a significant improvement in the communication of treatment goals (53% preimplementation vs 86% postimplementation). Early timing of referrals remains a significant issue.

 

Conclusions: Implementing the individualized care plan program was associated with better communication and accessibility of documented palliative treatment goals for patients with AML.

 

Implications for Practice: This study establishes a model of care that addresses symptom and disease burden in end-stage AML and provides valuable insight into the patient and family understanding of treatment intent during this terminal phase.